FRFidelia Elvira Da Costa Rao

Fidelia Elvira Da Costa Rao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fidelia Elvira Da Costa Rao has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparison of angiotensin converting enzyme 1 levels to the grading of knee osteoarthritis

    by Fidelia Elvira Da Costa Rao, Femi Syahriani, Haerani Rasyid, Syakib Bakri, Harun Iskandar, M. Nasser Mustari, Gerald Wonggokusuma, Andi A. Zainuddin

  • Open Access

    Main Session: Gap junctions in myocardial disease

    by F. Rao, C. Deng, Y. Xue, Q. Zhang, H. Deng, S. Wu, N. Tribulova, T. Benova, C. Viczenczova, J. Radosinska, et al.

    Introduction: Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Recent findings have demonstrated a mechanistic link between inflammatory and the development of AF. Macrophage migration inhibitory factor (MIF), a pleiotropic cytokine, controls the inflammatory ‘set point’ by regulating the release of other pro-inflammatory cytokines. Recent studies have revealed that Connexin 43 (Cx 43) not only is involved in the electrical conductivity between the cells, but also forms a complex with PKP2 and Na+ channel to affect the sodium current. The purpose of this study is to observe the role of MIF in the expression of Cx43, and the role of Cx43 in the regulation of calcium channel current in atrial myocytes.

  • Open Access

    Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis

    by M. M. Fung, Y. Chen, M. S. Lipkowitz, R. M. Salem, V. Bhatnagar, M. Mahata, C. M. Nievergelt, F. Rao, S. K. Mahata, N. J. Schork, et al.

    End-stage renal disease (ESRD) due to hypertension is common and displays familial aggregation in African Americans, suggesting genetic risk factors, including adrenergic activity alterations which are noted in both hypertension and ESRD. We analysed 554 hypertensive nephrosclerosis participants (without clinically significant proteinuria) from the longitudinal National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) African American Study of Kidney Disease and Hypertension (AASK) cohort to determine whether decline in glomerular filtration rate (GFR) over approximately 3.8 years was predicted by common genetic variation within the adrenergic beta-1 (ADRB1) receptor at non-synonymous positions Ser49Gly and Arg389Gly. The polymorphism at Ser49Gly (though not Arg389Gly, in only partial linkage disequilibrium at r(2) = 0.18) predicted the chronic rate of GFR decline, with minimal decline in Gly(49)/Gly(49) (minor allele) homozygotes compared to Ser(49) carriers; concordant results were observed for haplotypes and diploid haplotype pairs at the locus. An independent replication study in 1244 subjects from the San Diego Veterans Affairs Hypertension Cohort confirmed that Gly(49)/Gly(49) homozygotes displayed the least rapid decline of eGFR over approximately 3.6 years. We conclude that GFR decline rate in hypertensive renal disease is controlled in part by genetic variation within the adrenergic pathway, particularly at ADRB1. The results suggest novel strategies to approach the role of the adrenergic system in the risk and treatment of progressive renal disease.